Ψ-2C-DFMO
| Clinical data | |
|---|---|
| Other names | ψ-2C-O-35; 4-Difluoromethoxy-2,6-dimethoxyphenethylamine |
| Routes of administration | Oral |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | ~18 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C11H15F2NO3 |
| Molar mass | 247.242 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ψ-2C-DFMO, also known as ψ-2C-O-35 or as 4-difluoromethoxy-2,6-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and ψ-phenethylamine families. It is the phenethylamine (α-demethyl) analogue of ψ-DODFMO and is also structurally related to other psychedelics like difluoromescaline (DFM) and 2C-T-35 (2C-T-DFM). The drug has been found to be active at a dose of 17 mg orally, with moderately intense effects and a relatively long duration of around 18 hours. Ψ-2C-DFMO was first described in the scientific literature by Daniel Trachsel in 2012. It is a controlled substance in Canada under phenethylamine blanket-ban language.